JIPMER Invites Applications for 4 Certificate Courses, Check All Details Here

Puducherry- Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) is inviting applications from interested candidates for admission to Certificate Courses for session 2024-25. Applications are invited for 4 certificate courses – Emergency Medical Technician, Qualified Mortuary Assistant (QMA), Enterostomal Therapy Nursing and Phlebotomy.

Interested and eligible candidates who are willing to take admission to said Certificate Courses can download the application form from the official website of JIPMER. Therefore, the filled-in application with necessary enclosures i.e. Xerox copy of the Birth Certificate,12th Mark Sheet & Degree Certificate – for Enterostomal Therapy must be submitted to the Academic Section addressed to The Dean (Academic), JIPMER on or before 08 February 2025 up to 4:30 pm.

Also Read: JIPMER notifies on Orientation Program for MBBS Interns For February 2025 Batch, Details

Moreover, the walk-in counselling for eligible candidates will be held on 13 February 2025 at JIPMER Academic Section, III-Floor, JIPMER Academic Center and the registration will start from 09:00 am to 10:30 am. However, candidates will not be permitted after 10.30 A.M.

However, after the closure of Registration, the Merit list among those candidates present for counselling will be drawn based on the Marks obtained in Physics, Chemistry, Botany, Zoology or Biology put together / B.Sc. (Nursing) Mark Candidates will be selected as per their merit ranking and the remaining candidates would be wait-listed for a future vacancy, if any.

In this regard, JIPMER has also issued a notification detailing the Qualifications, fees, documents, vacant seats, etc. Below are the details-

DOCUMENTS

Meanwhile, candidates are required to bring the following Original certificates. Bonafide certificates will not be entertained-

1 +2 Mark sheet.

2 Transfer Certificate.

3 Conduct Certificate.

4 Birth Certificate.

5 Residence Certificate.

6 B.Sc Nursing Degree Certificate – for Enterostomal Therapy).

7 One set of photocopies.

8 2 Passport-size photographs for counseling.

FEES

Apart from this, the candidates should undergo a Medical Examination and pay Rs 130/- (one time) as fees and Rs 1,000/- as a Caution Deposit on the same day i.e. 14 February 2025. After this, The course commences from 15 February 2025. Additionally, the stipend will be offered during the course period and during the optional internship period i.e. Rs.300/- per month during the course period and Rs.3,713/- per month during the optional internship period. Also, on successful completion of the training course and evaluation by the Faculty of JIPMER, a Course completion certificate will be issued.

OTHER DETAILS

S.NO

NAME OF THE COURSE

QUALIFICATION

AGE

TOTAL NO. OF SEATS

DURATION OF THE COURSE

1

Emergency Medical Technician.

who had completed +2 (Science / Vocational stream with MLT/Nursing).

17 to 25 years as on 31.12.2024

20

12 Months + 1 Year Optional Internship

2

Qualified Mortuary Assistant (QMA).

who had completed +2 (Science with Biology).

17 to 25 years as on 31.12.2024

02

12 Months + 1 Year Optional Internship

3

Enterostomal Therapy Nursing.

B.Sc. Nursing with One year of clinical experience.

30 years as on 31.12.2024

02 / every 03 months Every year 08

03 Months

4

Phlebotomy.

who had completed +2 (Science with Biology).

17 to 25 years as on 31.12.2024

08

12 Months (6 months training and 6 months compulsory internship)

To view the notification, click the link below

https://medicaldialogues.in/pdf_upload/jipmer-271934.pdf

Powered by WPeMatico

GSK Depemokimab applications accepted for review in China, Japan for asthma with type 2 inflammation, CRSwNP

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, Labour and Welfare for use of depemokimab in two indications.

In China, the submitted indications are for an add-on maintenance treatment of asthma in adult and adolescent patients aged 12 and older with type 2 inflammation characterised by blood eosinophil count, and add-on maintenance treatment of adult patients with inadequately controlled CRSwNP. In Japan, the submitted indications are for treatment of severe or refractory bronchial asthma and CRSwNP inadequately controlled with standard treatment.

Kaivan Khavandi, SVP, Global Head of Respiratory/Immunology R&D, said, “Simultaneous regulatory submissions for two indications highlight our confidence in depemokimab to help reduce the burden of both asthma and CRSwNP for patients and health systems. Our SWIFT and ANCHOR trials support depemokimab’s potential to suppress IL-5, a known driver of type 2 inflammation, to offer patients sustained inhibition of a key driver of their disease with just two doses per year.”

Depemokimab, a monoclonal antibody that targets interleukin-5 (IL-5), is the first ultra-long-acting biologic to be evaluated in phase III trials and be accepted for regulatory review for use in these conditions. Depemokimab’s extended half-life, high-binding affinity and potency, support six month (26 week) dosing regimens based on results from the SWIFT and ANCHOR trials. In asthma patients and patients with CRSwNP, these trials showed depemokimab could offer sustained inhibition of a key driver of their disease, and help achieve key clinical outcomes with a dosing schedule of just two injections per year.1-3 Longer intervals between doses have been shown to overcome barriers to optimal care such as patient adherence.4

IL-5 is a key cytokine (protein) in type 2 inflammation. Type 2 inflammation is typically identified by blood eosinophil count and is an underlying driver in many diseases. This type of inflammation is present in the majority of patients with difficult to treat asthma and can lead to exacerbations and hospitalisation. Type 2 inflammation is also present in up to 80% of people with CRSwNP and is associated with more severe disease and symptoms.

Asthma is a major health burden in China affecting an estimated 46 million adults with approximately 15.5% reporting to have experienced an exacerbation requiring a hospital visit in the last 12 months.

CRSwNP is a chronic condition that affects up to 4% of the general population, of whom 40% have uncontrolled disease. It is estimated that about 107 million people in China suffer from chronic sinusitis, about 1/3 of whom have chronic sinusitis with nasal polyps. In Japan, it is estimated that there are 2 million people with chronic sinusitis, of which about 200,000 are subject to surgery due to nasal polyps.

Depemokimab is currently not approved in any country.

Powered by WPeMatico

NMC to Constitute Speciality Expert Committee for PG specialisations, seeks faculty participation

New Delhi: Informing about the constitution of a Specialty Expert Committee (SEC) for each speciality, the National Medical Commission has asked willing faculties/ specialists to furnish their details by 15th February 2025.

Writing to the Principal/Dean of all PG medical colleges under NMC, the Executive Director of the National Board of Examinations in Medical Sciences (NBEMS), and the Dean/Principal of all Institutes of National Importance, NMC Secretary Dr. B Srinivas addressed the issue of constitution of speciality expert committee of various postgraduate specialties.

“Kindly find enclosed letter no. N-P050(20)/52/2024-PGMEB-NMC (e8312123) dated 14th January, 2025 w.r.t. decision of Post Graduate Medical Education Board (PGMEB) to constitute a Specialty Expert Committee (SEC) for each specialty listed in PGMER-2023,” NMC mentioned in the communication.

“All concerned stakeholders are requested to kindly take note of the same and willing faculties/ specialist may furnish their details by 15th Feb, 2025,” the Commission added.

Also Read: Patients can file appeals against state medical councils orders: NMC

In this regard, the Postgraduate Medical Education Board (PGMEB) of NMC had written to the PG medical college heads, Deans of INIs and NBEMS Executive Director on 14.01.2025. 

The PG Board of NMC had informed that the Specialty Expert Committees were being set up to enhance the quality and uniformity of postgraduate medical education. These committees will have the responsibility to prepare a model curriculum and develop speciality-specific Assessment forms for assessing institutes besides addressing other academic requirements of specialities.

Back then, the NMC PG Board had asked the willing faculties/specialists to furnish their details. “Post-Graduate Medical Education Board (PGMEB) of National Medical Commission (NMC), with a view to enhance the quality and uniformity of post-graduate medical education, has decided to constitute a Specialty Expert Committee (SEC) for each specialty as listed in the Post Graduate Medical Education Regulations-2023. These committees will be responsible for preparing a model curriculum and developing specialty specific Assessment forms for assessing institutes besides addressing other academic requirements of specialties,” the PG Board mentioned in the notice.

“The Faculty/Specialists of various specialties, who are willing to contribute towards this initiative, are requested to furnish their details within 15 days from the date of publication of this notice on the link given below (which may be copied and pasted on a new webpage),” it added.

The Commission had further mentioned that all the faculty/specialists working in Private/Government medical colleges, including Institutes of National Importance/NBEMS-recognized medical institutions, were eligible to contribute towards this initiative.

For this, the willing faculties/specialists were asked to furnish their details using the link mentioned in the notice.

To view the NMC notice, click on the link below:

https://medicaldialogues.in/pdf_upload/nmc-specialty-expert-committee-272435.pdf

Also Read: NMC issues Warning About Impersonators targeting medical colleges for money

Powered by WPeMatico

Apollo Hospitals launches third cancer centre in Chennai

Chennai: Apollo Hospitals proudly inaugurated its third cancer centre in Chennai. This comprehensive cancer centre at Vanagaram was inaugurated by Mr. Ma. Subramanian, Hon’ble Minister for Health and Family Welfare, Government of Tamil Nadu, and Ms. Supriya Sahu IAS, Additional Chief Secretary, Department of Health & Family Welfare, Government of Tamil Nadu along with Dr Prathap C Reddy, Founder & Chairman, Apollo Hospitals Enterprise Ltd (AHEL), Dr. Preetha Reddy, Vice Chairperson, AHEL, and Ms. Suneeta Reddy, Managing Director, AHEL.

Mr. Ma. Subramanian, Hon’ble Minister for Health and Family Welfare, Govt. of Tamil Nadu said, “Our focus is in synergy with bringing advanced cancer care to Tamil Nadu, and we’re happy that Apollo Cancer Centres is constantly bringing newer and innovative technologies to the State and extending it across India and globally. I applaud ACCs and the team for their tireless efforts in revolutionizing cancer care in India. The inauguration of Apollo Cancer Centre at Vanagaram is a significant milestone in our collective fight against cancer.”

Dr Prathap C Reddy, Founder & Chairman, Apollo Hospitals Enterprise Ltd., said, “At Apollo Hospitals, our mission is to bring world-class healthcare to the people of India, and we are committed to investing in the latest technology and infrastructure to achieve this.

The opening of our new centre in Vanagaram will considerably enhance access to top-tier cancer care for patients across Chennai and the surrounding region. This launch aligns with our vision of a future where cancer is no longer a life-threatening disease, but a manageable condition. We will continue to strive towards this goal by investing in research, innovation, and the best possible care for our patients.”

Also Read:Apollo Hospitals Partners with Indonesia’s Mayapada Healthcare to boost healthcare services

Ms. Supriya Sahu IAS, Additional Chief Secretary, Dept of Health & Family Welfare, Govt. of Tamil Nadu, said, “This new centre, quality cancer care is being brought closer to the people, ensuring that no one is deprived of the treatment they deserve. This is a significant step towards a healthier and more resilient community.”

Speaking during the event Dr. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Enterprise Ltd., said, “Apollo Hospitals continues to lead the nation in cancer care by setting new benchmarks in treatment, innovation, and patient support. The launch of Apollo Cancer Centre in Vanagaram, which is equipped with Tamil Nadu’s first Elekta Harmony Pro radiation therapy technology, is a testament to this commitment. This facility has now brought advanced oncology services closer to home, reducing travel time and increasing convenience for patients and their caregivers. The inauguration of our 23rd Cancer Centre underscores our dedication to providing world-class cancer care accessible to every patient.”

A key feature of the Apollo Cancer Centre at Vanagaram is its standalone dedicated unit, which provides comprehensive cancer care. The Centre offers advanced diagnostic services, surgical and radiation oncology, and support from allied specialized medical professionals such as counsellors, dieticians, and speech therapists.

The Centre comprises a dedicated multidisciplinary team comprising renowned oncologists from various specialties, including medical oncology, radiation oncology, surgical oncology, pathology, and nursing. This team works together to create and implement comprehensive treatment plans that are specific to each patient’s needs, ensuring holistic and compassionate care. Their organ-specific cancer management teams at the Vanagaram centre will focus on tailoring treatment strategies to the unique characteristics of cancers in particular organs.

Also Read:Apollo Hospitals Bhubaneswar Sets Milestone with Successful Liver Transplants

Powered by WPeMatico

Sanofi Sarclisa approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplant (ASCT) based on data from the IMROZ phase 3 study.

Olivier Nataf, Global Head, Oncology said, “When Sanofi entered China more than four decades ago, we did so with the intention of bringing potentially transformative therapies to Chinese patients. This approval, occurring just weeks after Sarclisa’s first in the country, represents tremendous progress towards advancing this mission. Now, patients with multiple myeloma and their providers have access to two new Sarclisa-based regimens that have the potential to improve outcomes across lines of therapy.”

This approval closely follows the decision from the NMPA earlier in January 2025, approving Sarclisa in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with relapsed or refractory MM (R/R MM) who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. Beyond China, in the Asia-Pacific region, a regulatory submission for Sarclisa in NDMM patients not eligible for hematopoietic stem cell transplantation (HSCT) is currently under review in Japan.

Sarclisa (isatuximab) is a CD38 monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity. CD38 is highly and uniformly expressed on the surface of MM cells, making it a target for antibody-based therapeutics such as Sarclisa. In the US, the non-proprietary name for Sarclisa is isatuximab-irfc, with irfc as the suffix designated in accordance with nonproprietary naming of biological products guidance for industry issued by the US Food and Drug Administration.

Currently, Sarclisa is approved in more than 50 countries, including in the US, EU, Japan, and China, across multiple indications. Based on the ICARIA-MM phase 3 study, Sarclisa is approved in the US, EU and Japan in combination with Pd for the treatment of patients with R/R MM who have received ≥two prior therapies, including lenalidomide and a proteasome inhibitor; this combination is also approved in China for patients who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. Based on the IKEMA phase 3 study, Sarclisa is also approved in more than 50 countries in combination with carfilzomib and dexamethasone, including in the US for the treatment of patients with R/R MM who have received one to three prior lines of therapy and in the EU for patients with MM who have received at least one prior therapy. In the US, EU, and China, Sarclisa is approved in combination with VRd as a front-line treatment option in transplant-ineligible NDMM patients, based on the IMROZ phase 3 study.

Sanofi continues to advance Sarclisa as part of a patient-centric clinical development program, which includes several phase 2 and phase 3 studies across the MM treatment continuum spanning six potential indications. In addition, the company is evaluating a subcutaneous (SC) administration method for Sarclisa in clinical studies. In January 2024, Sanofi reported positive results from the IRAKLIA phase 3 study evaluating Sarclisa SC formulation administered via an on-body delivery system (OBDS) in combination with Pd compared to intravenous (IV) Sarclisa in patients with R/R MM. In December 2024, additional positive results from the program, including the GMMG-HD7 phase 3 study evaluating Sarclisa-RVd induction therapy in transplant-eligible NDMM patients, were also presented at the 66th American Society of Hematology Annual Meeting and Exposition. The safety and efficacy of Sarclisa has not been evaluated by any regulatory authority outside of its approved indications and methods of delivery.

Powered by WPeMatico

GMC Sindhudurg to receive manpower, infrastructure upgrades

Mumbai: To address faculty and infrastructure challenges, Maharashtra Medical Education Minister Hasan Mushrif has directed immediate action to enhance facilities at Government Medical College (GMC) Sindhudurg. During a meeting at the Ministry, he instructed officials to provide the necessary equipment, manpower, and resources to the institution without delay.

Addressing the vacant professor positions at the medical college, Mushrif set a six-month deadline to fill these positions and directed that Class III and Class IV positions, including technical and non-technical staff, should be hired through external agencies. 

Also read- NMC gives nod to GMC Sindhudurg for 100 MBBS Seats

He stressed the need for transparency in the recruitment process and urged that all positions be filled within the next eight months. Further, he suggested transferring faculty from surplus locations to Sindhudurg to ensure the smooth functioning of the college.

According to Medical Education Commissioner Rajeev Nivatkar, advertisements for the recruitment of professors have already been published, and the hiring process is expected to be completed by May. The Class III, Class IV, technical, and non-technical positions will be filled within the next eight months, as confirmed by Commissioner Rajeev Nivatkar.

Infrastructure improvements were also discussed, with Hasan proposing the demolition of the Nursing College hostel building to the health department. He emphasized the need for temporary accommodations for students.

“For this purpose, rental spaces should be acquired, and department officials should visit the college to assess the situation, provide necessary information on improvements, and expedite the construction of new buildings,” he said as reported by Free Press Journal. 

Fisheries and Ports Development Minister Nitesh Rane also highlighted the importance of equipping the medical college with essential medical infrastructure. He recommended that the recruitment process for Class III and Class IV positions be transparent, and that measures be taken to ensure quality healthcare services for the public at the college. He also emphasised the need to allocate funds for medicines.

The government is also working on a land acquisition proposal to allocate 13 acres of land for the Government Medical College. Of this, three acres have already been approved from the Industrial Training Institute (ITI) land under the Skill Development Department, while the remaining 10 acres are set to be acquired from the Social Forestry Department.

Also read- Maha CET Cell issues notice on choice filling for admissions at newly NMC permitted medical college, Details

Powered by WPeMatico

Supreme Court Relief! WB Doctors’ PG Degrees Who Completed Studies By July 2022 UPHELD

New Delhi: Modifying its earlier order, the Supreme Court has now granted relief to many medical professionals in West Bengal by ensuring that those who completed their studies by July 2022 and were employed as senior residents would retain their degrees as legal and valid.

The top court bench on 17.10.2022 refused to consider their admission to the PG courses (for the 2019-2020 academic year) beyond the cut-off date of May 31, 2019.

Medical Dialogues had earlier reported that back in 2022, the top court bench had reiterated the need for strictly adhering to the admission time schedule and accordingly cancelled the PG medical admission of eight MBBS doctors, who had been earlier given relief by the Calcutta High Court.

However, the Apex Court bench of Justices Ajay Rastogi and CT Ravikumar had set aside the HC order while noting that the High Court had ignored the principles of merit while granting provisional admissions to those doctors and later while regularising them.

The case concerned eight MBBS doctors, who after clearing the NEET-PG 2019 examination, sought admission in the State quota seats in Post-graduate medical courses in medical colleges of West Bengal for the academic year 2019-2020. For the concerned year, the cut-off date for admission was May 31, 2019. However, even after the cut-off date, approximately 153 State quota PG medical seats remained vacant and the concerned students failed in their attempt after participating in the last counselling in securing admission to post­graduate medical seat in any of the speciality because of their much lower rank in the order of merit.

Also Read: NO Relief: Supreme Court cancels delayed PG medical admissions of 8 MBBS doctors, says schedule must be followed strictly

Even though the HC had granted them relief, the top court bench cancelled their admissions while noting, “In our considered view, no sympathy can be shown to such students who have not only entered/admitted after 31st May of the year but their admissions were completely in contravention to the Regulations, 2000 and provisional admissions were granted by the High Court ignoring the principle of merit which is the sole touchstone for admission to the post­graduate courses based on the NEET examination, 2019 where admissions are made strictly in the order of merit­ cum­ preference and despite the stay order passed by this Court, if they are allowed to continue in post­graduate medical courses, the same would be completely illegal and such contemptuous action on the part of the authorities, cannot be approved by this Court.”

Following this, the petitioner doctors filed a review petition before the Supreme Court and the matter was heard by a Division bench of Chief Justice Sanjiv Khanna, Justice Sanjay Kumar and Justice KV Vishwananthan.

As per the latest media report by Live Law, noting that the degrees were awarded to them in July 2022 i.e. before the date of the judgment, the Apex Court validated the medical degrees of the petitioners who had completed their education and were working as senior residents by July 2022.

“Having heard learned counsel for the parties and considering the peculiar facts and circumstances of the case, the present review petitions are entitled to be allowed to the extent that the review petitioners who have completed their studies in the month of July 2022 and were thereafter appointed and working as Senior Residents should not be deprived of their degrees. In other words, the degrees granted to them shall be treated as legal and valid, notwithstanding the judgment dated 17.10.2022 of this Court passed in the civil appeal,” the Court was quoted noting by Live Law.

However, this relief was not extended to one of the petitioners as the Court noted that his studies were ongoing at the time of the judgment. Instead, the Court allowed the concerned petitioner to continue his studies at North Bengal Medical College, Darjeeling, West Bengal whole noting that he was prevented from continuing his further studies in view of the judgment dated 17.10.2022.

“Keeping in view the fact that Dr. ***Sharma has already studied for about three years, we permit her to continue and complete her studies at North Bengal Medical College, Darjeeling, West Bengal,” observed the bench.

The top court bench also imposed a fine of Rs 5 lakh on West Bengal University of Health Sciences and North Bengal Medical College, holding them accountable for the litigation issues. The bench directed the University to deposit the amount in Chief Minister’s Relief Fund, Government of West Bengal, within four weeks.

Also Read: NEET PG Admissions: Domicile-Based Reservation Unconstitutional!- Supreme Court

Powered by WPeMatico

KGMU to offer Advanced NB-UVB Treatment for Vitiligo, Psoriasis

Lucknow: In a recent move to bolster healthcare services, King George’s Medical University (KGMU) is set to offer advanced treatment for conditions like vitiligo (leukoderma) and psoriasis. The institution is set to install a state-of-the-art NB-UVB UVA chamber machine, providing advanced therapy for skin disorders, with an allocated budget of Rs 15 lakh.

Narrow-band ultraviolet B (NB-UVB) technology involves using specific UVB light wavelengths to treat conditions like vitiligo, psoriasis, and severe itching (pruritus) by exposing the affected areas of the body to targeted light therapy.

Also Read: Misdiagnosed for years, Elderly man’s life saved by rare tumour surgery at KGMU

According to Prof. Swastika Suvirya, the head of KGMU’s dermatology department, this method is not only safe and painless but also comes without any additional treatment costs. Furthermore, studies have shown that it is suitable for use in children and pregnant women, making it a versatile option for a wide range of patients.

Along with this development, KGMU is also preparing to introduce postgraduate (PG) courses in dermatology. The university has submitted an application to the National Medical Commission (NMC) for approval, and an inspection is scheduled to take place soon.

Speaking to TOI, Prof. Swastika Suvirya said, “We already have the necessary infrastructure for starting PG courses. Some additional machines and equipment are being procured, and we have applied for course recognition. We are hopeful that the courses will begin in the next academic session after the inspection.”

Also Read: KGMU to acquire New Vacuum Suction Machine to Boost Prosthetic Care

Medical Dialogues had earlier reported that in a significant step to revolutionize prosthetics, the King George’s Medical University (KGMU), is set to acquire a vacuum suction machine designed to improve the fit and comfort of artificial prosthetic limbs. The new machine, which costs around 8-10 lakhs, will facilitate more precise production of prostheses. This advanced technology is expected to reduce common issues such as air gaps, misalignment, and discomfort that are often seen in traditional prosthetic limbs.

Powered by WPeMatico

DMER Haryana Begins NEET PG 2024 Round 3 Counselling, Check Key Dates

Haryana- Department of Medical Education and Research (DMER) Haryana has begun the state National Eligibility and Entrance Test-Postgraduate (NEET PG) Round 3 counselling for the academic year 2024-25.

The schedule has been released on the official website of DMER Haryana, therefore, candidates who are willing to participate in the counselling process for admission to MD/MS/DNB/Diploma Courses in MD/MS Programme Government/Government Aided/Private Unaided Medical Institutions can check the schedule here to know the programme-wise details.

Also Read: DMER Haryana to begin NEET PG Counselling registrations on October 18

As per the schedule, Haryana NEET PG Round 3 Counselling 2024 will run till February 3, 2025. The registration link will remain active till 11:59 pm. Students are advised not to wait for the last date of counselling registration and apply as soon as possible to avoid last-minute discrepancies. Along with registration, students will also be able to edit the information added to the registration form.

Meanwhile, the NEET PG Round 3 counselling 2024 choice filling and locking process will also continue till February 3, 2025. After this, the allotment of seats will be published on February 06, 2025, on the official website for the candidates.

NEET PG ROUND 3 COUNSELLING 2024 ELIGIBILITY

Candidates must fulfil the following specific eligibility criteria to participate in the round 3 registration for Haryana NEET PG counselling 2024-

1 Students who have not been allotted a seat in the Round 1 and Round 2 counselling process. 2 The candidates who have secured a seat but have not joined the allotted seat.

3 Candidates who have joined the allotted seat but have opted for an upgrade are eligible for the Round 3 counselling process.

FEES

Candidates have to deposit a security amount based on their category and preference for Haryana NEET PG counselling 2024 round 3. The expected fee is ₹25,000 (₹12,500 for reserved categories of Haryana state) for government/government-aided private medical colleges and ₹2,00,000 for private medical colleges and private universities.

DOCUMENTS

1 Class 10 certificate as proof of date of birth.

2 Certificate of MBBS pass from a recognised institute by NMC.

3 Three recent passport-size photographs, the same as used in the NEET PG application form.

4 Internship completion certificate.

5 Character certificates from the last attended institute.

6 Certificate of registration with any state medical council/ NMC.

7 Result of NEET PG 2024.

8 Any government-issued valid ID.

9 Printout of the Haryana NEET PG 2024 application form.

Also Read: DMER Haryana Revises NEET 2024 Round 2 Counselling Schedule, Registrations Extended to September 21

Powered by WPeMatico

Doctors Cite Lack of Scientific Studies on Adverse Effect, Urge Govt to Postpone Introducing Revised 5G Radiation Norms

Mumbai: Pointing out the possible public health risks, cybersecurity threats and environmental concerns, doctors from across the country have urged the Union Ministry of Communications to postpone the introduction of revised 5G radiation norms.

As per the doctors, the norms which are scheduled to come into effect from February 1, lack transparency and public engagement. Therefore, doctors and other citizens from Mumbai, Delhi and different cities across India have urged the Government to defer implementation of the new norms.

The initiative has been launched under the banner of Awaken India Movement (AIM), FPJ has reported. AIM has also initiated an online petition to support this cause.

Opposing the recent relaxations in the 5G radiation rules as the power density for a 5G Base Tower Station has been increased to 5 watts per square meter from 1 watt, the organisation has alleged that the Union Government has not conducted or published any studies to rule out possible health effects when more than 200 peer-reviewed studies across the world and 40 peer-reviewed studies in India have showed the possible health hazards from the EMF Radiation.

Also Read: 174-bed cancer hospital coming up at cost of Rs 213 crores in Bandra West

As per the latest media report by Free Press Journal, as per the data received under the Right to Information (RTI) Act, the Science and Engineering Research Board (SERB), a statutory research body under the union government’s Department of Science and Technology, has conducted no studies to assess the biological and ecological impacts of cellular technologies.

Further, the organization also cited an advisory by the Wildlife Division of the Ministry of Environment, Forest and Climate Change stating that the electromagnetic radiation can affect the biological systems of animals, bird,s and insects. It also alleged contradictions in statements issued by the Indian Council of Medical Research (ICMR), which had previously claimed to have conducted studies on the health impacts of radiation but later denied ever conducting such research.

Writing to the Union Ministry, AIM raised concerns regarding the long-term health impacts of electromagnetic radiation (EMR) exposure, specifically to vulnerable populations such as children, the elderly, and those with pre-existing health conditions. It also expressed its concerns over the fact that the risk of cyberattacks has increased with the rapid deployment of 5G network. Such cyberattacks include financial fraud, data breaches, and privacy violations.

Further, the doctors have highlighted the environmental concerns concerning the deployment of 5G network, while painting out that the infrastructure necessary for 5G, especially for the deployment of small cell antennas and increased energy consumption by the network, may exacerbate global environmental challenges. The doctors also alleged that wireless technology is the reason for the demise of frogs, bats, honey bees and house sparrows.

Therefore, they have urged the Government to postpone the implementation of the revised norms and also pointed out in the letter that the delay is essential to conduct comprehensive, multidisciplinary studies, strengthen regulatory safeguards, and ensure robust public engagement.

“The government is failing in its duty to uphold Article 21 of the Constitution, which guarantees the fundamental right to health and safety. There is absolutely no regard for the elderly, infirm, pregnant women, young children, or flora and fauna who may be sensitive to such radiation. Failing to act responsibly now will not only jeopardize public health and cybersecurity but will also erode public trust in governance. The government must prioritize the safety and well-being of its citizens above economic expediency or technological progress,” the letter mentioned.

Also Read: Delete defamatory content against Serum Institute of India: Bombay HC directs two individuals

Powered by WPeMatico